Internal medicine

Immunotherapy

Disease

Progression-free survival

Overall survival

Cancer

Oncology

Lung cancer

Progressive disease

Response Evaluation Criteria in Solid Tumors

Nivolumab

Medicine

Journal of Thoracic Oncology

Nivolumab is effective in the treatment of previously treated patients with advanced NSCLC. However, its radiological evaluation is challenging because of atypical patterns of response such as pseudoprogression. We examined the characteristics and outcomes of previously treated patients with NSCLC who were treated with nivolumab and experienced development of pseudoprogression.

Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy